Skip to main content

Table 3 Visual function questionnaire-25 score

From: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

VFQ-25 Score

ITT population (N = 125)

PP population (N = 116)

Baseline, mean ± SD

60.9 ± 14.36

60.4 ± 14.14

Week 12, mean ± SD

66.7 ± 12.65

66.5 ± 12.50

Mean ± SD change from baseline to Week 12

5.8 ± 10.78 [p < 0.001]

6.1 ± 10.96 [p < 0.001]

Week 24, mean ± SD

69.5 ± 12.46

69.5 ± 12.35

Mean ± SD change from baseline to Week 24

8.5 ± 13.04 [p < 0.001]

9.2 ± 13.33 [p < 0.001]

  1. ITT intent-to-treat population, PP per-protocol population